NeoGenesis Capital

NeoGenesis Capital has announced the launch of a new investment fund focused on two frontier areas: superintelligence and synthetic biology. The firm will back companies working on advanced artificial intelligence and engineered biological technologies. Details on the fund's size, investors, or specific portfolio targets have not been disclosed, and reaction from the tech and biotech communities is still limited.

Peter Diamandis, founder of the XPRIZE Foundation, has launched NeoGenesis Capital, a new venture firm created to invest in Colossal Biosciences and its work on programmable biology. Colossal, known for its de-extinction projects such as the woolly mammoth, aims to engineer biological systems using genetic tools. The move signals growing investor interest in synthetic biology.